MARKET

CDXS

CDXS

Codexis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.42
+0.05
+0.37%
After Hours: 13.42 0 0.00% 16:00 08/13 EDT
OPEN
13.41
PREV CLOSE
13.37
HIGH
13.55
LOW
13.26
VOLUME
159.47K
TURNOVER
--
52 WEEK HIGH
18.87
52 WEEK LOW
8.43
MARKET CAP
793.48M
P/E (TTM)
-52.9180
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CDXS stock price target is 18.83 with a high estimate of 23.00 and a low estimate of 15.00.

EPS

CDXS News

More
Codexis Reports Second Quarter 2020 Financial Results
Revenues increased 21% to $15 million; 72% rise in R&D revenue included a significant contribution from the Takeda biotherapeutics partnership Conference call with slides begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWI
GlobeNewswire · 08/06 20:05
Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors
Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors Dr. Jennifer L. AakerREDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announced t
GlobeNewswire · 08/06 11:00
Codexis to Hold Second Quarter 2020 Conference Call on August 6
REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after market close on Thursday, August 6, 2020. Codexis management
GlobeNewswire · 07/30 11:00
Earnings Preview: Codexis (CDXS) Q2 Earnings Expected to Decline
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
A Green Light for Shares of Sherwin-Williams
marketwatch.com · 06/26 22:15
Codexis teams up Molecular Assemblies in the field of DNA synthesis
Seeking Alpha - Article · 06/23 13:15
Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthesis
GlobeNewswire · 06/23 12:00
Codexis and Molecular Assemblies Announce DNA Synthesis Partnership
REDWOOD CITY, Calif. and SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company and developer of high-performance enzymes, and Molecular Assemblies, Inc., a
Benzinga · 06/23 11:06

Industry

Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
-0.06%

Hot Stocks

Symbol
Price
%Change

About CDXS

Codexis, Inc. is a protein engineering company. The Company is engaged in the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. The Company operates through its two segments, such as the performance enzymes and novel biotherapeutics. It provides enzyme optimization services from small scale through to commercial quantities and also develops biocatalyst products. It is also engaged in the development of manufacturing processes for active pharmaceutical ingredients, fine chemicals and food ingredients. Its CodeEvolver is a protein engineering technology platform and products in the pharmaceuticals market. The Company serves various industries, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemical.
More

Webull offers kinds of Codexis, Inc. stock information, including NASDAQ:CDXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXS stock methods without spending real money on the virtual paper trading platform.